Phospholipase A2, Lipoprotein Associated (LpPLA2)

PLA2G7; PAF-AH; PAFAH; Lp-PLA2; LDL-PLA2; Platelet Activating Factor Acetylhydrolase,Plasma; Phospholipase A2,Group VII; LDL-associated phospholipase A2

SPN	V944
HGNC	9040
MGI	1351327
PubMed	22074435
RGD	1310734
UniProt	Q13093
Wiki	PLA2G7

Lipoprotein-associated phospholipase A2 (Lp-PLA2, also known as platelet activating factor acetyl-hydrolase), is a relatively recent marker that has emerged as a major, independent predictor of CHD. Lp-PLA2 is an active phospholipase that circulates in plasma bound to LDL, and it appears to act almost exclusively on oxidized LDL to generate lysophosphatidyl-choline, which is proinflammatory and is considered to be atherogenic. Thus, Lp-PLA2 represents an interesting link between lipoproteinoxidation and vascular inflammation, which likely explain its strong, independent association with CHD risk. Data from the recent ARIC study have indicated that the predictive power of Lp-PLA2 is attenuated after adjustment for multiple established risk factors.

Reference

"Anti-inflammatory properties of a platelet-activating factor acetylhydrolase."
Nature 374:549-553(1995) [PubMed] [Europe PMC] [Abstract]

"Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins."
Arterioscler. Thromb. Vasc. Biol. 16:591-599(1996) [PubMed] [Europe PMC] [Abstract]

"The DNA sequence and analysis of human chromosome 6."
Nature 425:805-811(2003) [PubMed] [Europe PMC] [Abstract]

"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."
Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]

"Plasma platelet-activating factor acetylhydrolase is a secreted phospholipase A2 with a catalytic triad."
J. Biol. Chem. 270:25481-25487(1995) [PubMed] [Europe PMC] [Abstract]

"Crystal structure of human plasma platelet-activating factor acetylhydrolase: structural implication to lipoprotein binding and catalysis."
J. Biol. Chem. 283:31617-31624(2008) [PubMed] [Europe PMC] [Abstract]

"Crystal structures of human group-VIIA phospholipase A2 inhibited by organophosphorus nerve agents exhibit non-aged complexes."
Biochem. Pharmacol. 78:420-429(2009) [PubMed] [Europe PMC] [Abstract]

"Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase."
J. Clin. Invest. 97:2784-2791(1996) [PubMed] [Europe PMC] [Abstract]

"Loss of activity of plasma platelet-activating factor acetylhydrolase due to a novel Gln281-->Arg mutation."
Biochem. Biophys. Res. Commun. 236:772-775(1997) [PubMed] [Europe PMC] [Abstract]

"A mutation in plasma platelet-activating factor acetylhydrolase (Val279-->Phe) is a genetic risk factor for stroke."
Stroke 28:2417-2420(1997) [PubMed] [Europe PMC] [Abstract]

"Identification of the G994--> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men."
Metabolism 47:177-181(1998) [PubMed] [Europe PMC] [Abstract]

"A mutation in plasma platelet-activating factor acetylhydrolase (Val279Phe) is a genetic risk factor for cerebral hemorrhage but not for hypertension."
Thromb. Haemost. 80:372-375(1998) [PubMed] [Europe PMC] [Abstract]

"The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma."
Am. J. Hum. Genet. 66:1522-1530(2000) [PubMed] [Europe PMC] [Abstract]